Skip to main content

Oligomerix Lands NIA Grant for Alzheimer's Biomarker Research

NEW YORK (GenomeWeb News) — Oligomerix said today that it has received a $323,000 grant from the National Institutes of Health's National Institute on Aging for research that could lead to diagnostic assays for Alzheimer's disease.

The New York, NY-based company plans to use the Small Business Innovation Research funding to develop a test that could monitor proteins in cerebrospinal fluid and plasma from AD patients. This research will be conducted by researchers at Columbia University Medical Center.

The company said that it will evaluate novel biomarkers by studying protein-protein interactions in search of new ways of diagnosing and monitoring AD.

"Our focus is to develop assays that can be used for drug discovery for AD," Oligomerix CEO James Moe said in a statement. "Any validated assays developed under this program for disease staging or definitive diagnosis of AD will be potential out-licensing opportunities for the company."

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.